AR077155A1 - Nanodispersion, nanoparticulas y solucion - Google Patents

Nanodispersion, nanoparticulas y solucion

Info

Publication number
AR077155A1
AR077155A1 ARP100102179A ARP100102179A AR077155A1 AR 077155 A1 AR077155 A1 AR 077155A1 AR P100102179 A ARP100102179 A AR P100102179A AR P100102179 A ARP100102179 A AR P100102179A AR 077155 A1 AR077155 A1 AR 077155A1
Authority
AR
Argentina
Prior art keywords
nanoparticles
nanodispersion
salts
solution
tacrolimus
Prior art date
Application number
ARP100102179A
Other languages
English (en)
Inventor
Ajay Jaysingh Khopade
N Arulsudar
Subhas Balaram Bhowmick
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of AR077155A1 publication Critical patent/AR077155A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Una nanodispersion estable que comprende nanopartículas que tienen un tamano promedio menor de 300 nm dispersadas en un vehículo que comprende un solvente miscible en agua y agua, comprendiendo dichas nanopartículas una o más drogas que tienen, un polímero y un surfactante que comprende una mezcla de ácidos grasos o sus sales y esterol o sus derivados o sus sales. Reivindicacion 2: Una nanodispersion en la forma reivindicada en la reivindicacion 1 en donde la droga se selecciona de un grupo que consiste de temsirolimus, tacrolimus, sirolimus, fenofibrato, ciclosporina, tacrolimus, brinzolamida o sus sales farmacéuticamente aceptables.
ARP100102179A 2009-06-19 2010-06-22 Nanodispersion, nanoparticulas y solucion AR077155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1468MU2009 2009-06-19

Publications (1)

Publication Number Publication Date
AR077155A1 true AR077155A1 (es) 2011-08-03

Family

ID=43355961

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102179A AR077155A1 (es) 2009-06-19 2010-06-22 Nanodispersion, nanoparticulas y solucion

Country Status (12)

Country Link
US (1) US8778364B2 (es)
EP (1) EP2442805A4 (es)
JP (1) JP5627039B2 (es)
KR (1) KR20120050414A (es)
CN (1) CN102802624A (es)
AR (1) AR077155A1 (es)
AU (1) AU2010261342A1 (es)
CA (1) CA2765541A1 (es)
EA (1) EA201270050A1 (es)
MX (1) MX2011013726A (es)
WO (1) WO2010146606A1 (es)
ZA (1) ZA201109510B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102970990A (zh) 2010-05-03 2013-03-13 帝国制药美国公司 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
KR102009698B1 (ko) 2011-12-20 2019-08-13 바이옴 테라퓨틱스 리미티드 진균 감염의 치료를 위한 국소 오일 조성물
CN103483353B (zh) * 2012-06-13 2016-02-24 上海现代药物制剂工程研究中心有限公司 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
JP6589086B2 (ja) * 2013-04-12 2019-10-16 ビョーメ セラピューティクス リミテッド 抗菌薬の組成物および製剤、その製造法および微生物感染症の治療方法
WO2015155703A2 (en) * 2014-04-09 2015-10-15 Nanoceutica Laboratories Pvt. Ltd Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
WO2015184238A1 (en) * 2014-05-30 2015-12-03 Oms Investments, Inc. Nano-sized water-based dispersion compositions and methods of making thereof
CN104798772B (zh) * 2015-03-13 2017-05-24 中国农业科学院农业环境与可持续发展研究所 一种农药纳米固体分散体及其制备方法
US11304898B2 (en) 2015-06-09 2022-04-19 Sun Pharma Advanced Research Company Ltd Method of treating carcinoma
CN108348468A (zh) * 2015-08-11 2018-07-31 Eyesiu医疗股份有限公司 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017129772A1 (en) * 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN114749656A (zh) * 2020-12-28 2022-07-15 航天神舟生物科技集团有限公司 一种金属纳米铁/纳米铜粒子溶液及工作液的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AU1809499A (en) 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations
KR19990075621A (ko) 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
WO2001021174A1 (en) 1999-09-23 2001-03-29 Dabur Research Foundation Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles
EP1408930A1 (de) * 1999-10-20 2004-04-21 Vesifact Ag Cyclosporine enthaltende mikroemulsion-prekonzentrate und mikroemulsionen
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
TWI230616B (en) 2000-09-25 2005-04-11 Ind Tech Res Inst Liposome for incorporating large amounts of hydrophobic substances
CA2445763A1 (en) 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20040092428A1 (en) 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US20040005339A1 (en) 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
ITMI20022323A1 (it) 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20050288521A1 (en) 2004-06-29 2005-12-29 Phytogen Life Sciences Inc. Semi-synthetic conversion of paclitaxel to docetaxel
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
BRPI0608173A2 (pt) 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
EP2138164A1 (en) 2005-06-17 2009-12-30 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
JP2009512682A (ja) 2005-10-21 2009-03-26 パナセア バイオテック リミテッド 少なくとも１種の抗癌性薬物および少なくとも１種のポリマーを含む医薬組成物
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
EP2076244B1 (en) 2006-10-10 2016-12-07 Jina Pharmaceuticals Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
US20100068251A1 (en) 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
WO2008144355A2 (en) 2007-05-17 2008-11-27 Morton Grove Pharmaceuticals, Inc. Stable, self-microemulsifying fenofibrate compositions
CA2710525C (en) * 2007-12-24 2017-08-22 Sun Pharma Advanced Research Company Limited Nanodispersion
US20100151037A1 (en) 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound

Also Published As

Publication number Publication date
EP2442805A1 (en) 2012-04-25
US20120087959A1 (en) 2012-04-12
EA201270050A1 (ru) 2012-05-30
JP2012530694A (ja) 2012-12-06
ZA201109510B (en) 2012-09-26
WO2010146606A1 (en) 2010-12-23
AU2010261342A1 (en) 2012-01-19
CA2765541A1 (en) 2010-12-23
MX2011013726A (es) 2012-02-29
KR20120050414A (ko) 2012-05-18
JP5627039B2 (ja) 2014-11-19
EP2442805A4 (en) 2012-11-21
CN102802624A (zh) 2012-11-28
US8778364B2 (en) 2014-07-15

Similar Documents

Publication Publication Date Title
AR077155A1 (es) Nanodispersion, nanoparticulas y solucion
CO6290681A2 (es) Nanodispersion
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2623233T3 (es) Composición farmacéutica tópica a base de alcanos semifluorados
CL2011002053A1 (es) Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel.
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
BRPI0810899A2 (pt) Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais.
EP4218724A3 (en) Microstructure array for delivery of active agents
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2006096806A3 (en) Treatment with statin and omega-3 fatty acids and a combination product thereof
ES2664584B2 (es) Nanoparticulas con interiores protegidos, y métodos de uso de las mismas
HRP20201179T4 (hr) Pripravci s kontinuiranim oslobađanjem na bazi nevodenih nosača
CL2012003350A1 (es) Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares.
AR065539A1 (es) Composiciones farmaceuticas que comprenden nanoparticulas que comprenden polimeros entericos y caseina
AR081535A1 (es) Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso
Shang et al. Recent advances on transdermal delivery systems for the treatment of arthritic injuries: From classical treatment to nanomedicines
BR112012015016B8 (pt) formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
BR112012004967B8 (pt) forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis, seu uso e seu método de produção
AR081520A1 (es) Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
Dehshahri et al. New horizons in hydrogels for methotrexate delivery
AR092840A1 (es) Elaboracion de degarelix
BRPI0418294A (pt) composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes
AR108562A1 (es) Método para la preparación del conjugado hialuronidasa con derivados de piperazina de polietileno y la aplicación del conjugado obtenido
EP3587392A8 (en) Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases

Legal Events

Date Code Title Description
FB Suspension of granting procedure